Kymera Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Kymera Therapeutics has a total shareholder equity of $395.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $575.8M and $180.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$374.88m |
| Equity | US$394.97m |
| Total liabilities | US$180.79m |
| Total assets | US$575.76m |
Recent financial health updates
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Recent updates
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Financial Position Analysis
Short Term Liabilities: KYMR's short term assets ($405.3M) exceed its short term liabilities ($85.7M).
Long Term Liabilities: KYMR's short term assets ($405.3M) exceed its long term liabilities ($95.1M).
Debt to Equity History and Analysis
Debt Level: KYMR is debt free.
Reducing Debt: KYMR had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KYMR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KYMR has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 48.7% each year.